STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $162,801 | -62.9% | 41,320 | 0.0% | 0.00% | – |
| Q2 2023 | $439,232 | +51.5% | 41,320 | +18.7% | 0.00% | – |
| Q1 2023 | $289,884 | +3.3% | 34,800 | +14.5% | 0.00% | – |
| Q4 2022 | $280,592 | -20.5% | 30,400 | +10.5% | 0.00% | – |
| Q3 2022 | $353,000 | +12.8% | 27,500 | +16.0% | 0.00% | – |
| Q2 2022 | $313,000 | -24.9% | 23,700 | +19.7% | 0.00% | – |
| Q1 2022 | $417,000 | -12.2% | 19,800 | 0.0% | 0.00% | – |
| Q4 2021 | $475,000 | +0.4% | 19,800 | +6.5% | 0.00% | – |
| Q3 2021 | $473,000 | -29.0% | 18,600 | -6.1% | 0.00% | – |
| Q2 2021 | $666,000 | -5.3% | 19,800 | +9.4% | 0.00% | – |
| Q1 2021 | $703,000 | -34.8% | 18,100 | +4.0% | 0.00% | -100.0% |
| Q4 2020 | $1,078,000 | +55.6% | 17,400 | -15.9% | 0.00% | – |
| Q3 2020 | $693,000 | +32.8% | 20,700 | -5.5% | 0.00% | – |
| Q2 2020 | $522,000 | +31.8% | 21,900 | +26.6% | 0.00% | – |
| Q1 2020 | $396,000 | – | 17,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |